

## **CRITICAL OUTCOME TECHNOLOGIES AWARDS STOCK OPTIONS**

**London, Ontario (October 23, 2014): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT; OTCQB: COTQF)**, the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it awarded 1,801,099 stock options to directors, officers, and employees under the Company's Stock Option Plan on October 22, 2014. The options awarded to directors were made as a retainer for their service on the Board and its committees for the ensuing year. The options were awarded to officers and employees by the Board on a discretionary basis for their meritorious efforts during the past year. The options have a five year life with 25% vesting occurring at the end of each quarter from the date of grant as applicable. The exercise price is \$0.29 and represents the closing price of the Company's common shares on October 21, 2014, the last trading day reported on the TSX Venture Exchange prior to the grant meeting date.

"Our history of compensating the Board of Directors with stock options for their service demonstrates the directors' belief and commitment to the Company's future," said Company Chairman, John Drake. "In keeping with this philosophy, the Board eliminated the practice of paying cash meeting fees effective with the recent Board meeting and increased the notional cash value of retainer compensation paid by issuing options thus reflecting management's belief in our key value-building initiatives such as COTI-2, our p53-dependent lead oncology program."

### **About Critical Outcome Technologies Inc. (COTI)**

COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI's proprietary artificial intelligence platform, CHEMSAS<sup>®</sup>, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

Critical Outcome Technologies Inc.  
Dr. Wayne Danter  
President & CEO  
Tel: 519-858-5157  
Email: [wdanter@criticaloutcome.com](mailto:wdanter@criticaloutcome.com)

Heisler Communications  
Trevor Heisler  
Investor Relations  
Tel: 416-500-8061  
Email: [trevor@heislercommunications.com](mailto:trevor@heislercommunications.com)

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*